Brandon Folkes, an analyst from H.C. Wainwright, maintained the Buy rating on Omeros. The associated price target remains the same with $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors surrounding Omeros’s potential market opportunity with Narsoplimab. The recent study published in the American Journal of Hematology highlights significant concerns regarding the use of eculizumab in pediatric patients with thrombotic microangiopathy following hematopoietic cell transplantation. This study found that eculizumab is associated with increased infection rates and infection-related mortality, which positions Narsoplimab as a potentially safer alternative if approved.
Folkes believes that the findings from this study could serve as a catalyst for Narsoplimab’s uptake, as it validates the clinical and commercial rationale for choosing Narsoplimab over eculizumab in treating TA-TMA patients. The study’s results underscore the potential advantages of Narsoplimab, which could lead to higher than anticipated market adoption and drive Omeros’s stock performance positively.